Sensyne Health PLC Issue of New Ordinary Shares & Total Voting Rights (1083H)
04 Avril 2022 - 8:01AM
UK Regulatory
TIDMSENS
RNS Number : 1083H
Sensyne Health PLC
04 April 2022
Sensyne Health plc
("Sensyne" or the "Company")
Issue of New Ordinary Shares and Total Voting Rights
Oxford, U.K. - 4 April 2022: Sensyne Health plc (LSE:SENS)
("Sensyne" or the "Company") today announces that it has issued a
total of 236,625 new ordinary shares of ten pence nominal value
("New Ordinary Shares") to the US health systems St. Luke's
University Health Network (St. Luke's) and Sentara Healthcare
("Sentara").
These New Ordinary Shares have been issued under the terms of
the previously announced strategic research agreements (SRAs) and
follow the completion of a valuation exercise as required under
Section 593 of the Companies Act.
Allocations were made as follows:
Health System New Ordinary Shares Allocated
St Luke's 115,541
------------------------------
Sentara 121,084
------------------------------
Total 236,625
------------------------------
Application has been made to the London Stock Exchange for the
admission of the 236,625 New Ordinary Shares to trading on AIM and
it is expected that admission will become effective and that
dealings will commence at 8.00 a.m. on 7th April 2022.
Total Voting Rights
Following the allotment of the New Ordinary Shares, the total
number of ordinary shares following admission will be 166,464,335
with each ordinary share carrying the right to one vote. The
Company has no shares in Treasury; therefore, following admission
the total number of voting rights in Sensyne will be 166,464,335.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify an interest in, or change to their interest in, the share
capital of the Company under the FCA's Disclosure and Transparency
Rules.
-ENDS-
Notes for editors:
About Sensyne Health : https://www.sensynehealth.com/
Sensyne Health plc (LSE: SENS) is a clinical artificial
intelligence company operating a unique business model - a
for-profit plc making a positive social impact, sharing the
financial returns it makes with health systems. The company applies
clinical AI in the healthcare and life science industries. In
healthcare, Sensyne delivers remote patient monitoring and
real-time decision-making systems for healthcare organisations and
their patients. In life sciences, Sensyne analyses large complex
anonymized data sets to help life sciences companies accelerate the
development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
Contact details:
Sensyne Health
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Dr Richard Pye, Chief Financial Officer +44 (0) 330 058 1845
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Liberum (Joint Broker)
Phil Walker + 44 (0) 20 3100
William Hall 2000
Consilium Strategic Communications
Mary-Jane Elliott +44 (0) 7780 600290
Jessica Hodgson
CSCSensynehealth@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPUMGCUPPUAC
(END) Dow Jones Newswires
April 04, 2022 02:01 ET (06:01 GMT)
Sensyne Health (LSE:SENS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Sensyne Health (LSE:SENS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024